Surveillance of immunization effectiveness and titer of type Ⅰ and type Ⅲ polio vaccine in Beijing before and after the adjustment of immunization strategy in 2012-2018
10.3760/cma.j.cn112150-20190621-00499
- VernacularTitle:2012—2018年免疫策略调整前后北京市Ⅰ和Ⅲ型脊髓灰质炎疫苗免疫效果及疫苗效价监测分析
- Author:
Juan LI
1
;
Zhujiazi ZHANG
;
Jingbin PAN
;
Herun ZHANG
;
Renqing LI
;
Maozhong LI
;
Li LU
;
Fang HUANG
;
Jiang WU
Author Information
1. 北京市预防医学研究中心 北京市疾病预防控制中心免疫预防所 100013
- Keywords:
Poliomyelitis;
Poliovirus vaccine, oral;
Vaccine effectiveness;
Vaccine titer
- From:
Chinese Journal of Preventive Medicine
2020;54(7):779-783
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the changing trend of polio vaccine immunization effectiveness and vaccine titer in Beijing in 2012, 2014, 2016 and 2018 before and after the adjustment of polio vaccine immunization program strategy.Methods:According to the convenient sampling method,the vaccination clinics of Chaoyang and Yanqing Districts in 2012, Fengtai and Daxing Districts in 2014, Tongzhou and Pinggu Districts in 2016, Dongcheng and Shunyi Districts in 2018 were selected as monitoring points. A total of 292 children were selected 4-8 weeks after the completion of 3 doses polio vaccine basic immunization which were 3 doses of trivalent oral poliovirus vaccine（tOPV）schedule before the strategy adjustment in 2012-2014 and 1 dose of inactivated poliovirus vaccine (IPV) following 2 doses of bivalent oral poliovirus vaccine (bOPV) sequential schedule after the adjustment in 2016-2018. About 1.0 ml blood samples were collected to detect type Ⅰ and Ⅲ neutralizing poliovirus antibody. A total of 9 oral poliovirus vaccines (8 vaccines in 2012) were selected from different sources of vaccine storage every year to test the vaccine titer using random number method .Results:The [ M（ P25， P75）] age of 292 children was 5 (5, 6) months, and the ratio of male to female was 1.04 (149/143). In 2012, 2014, 2016 and 2018, 66,72,68 and 86 children were investigated respectively. After basic immunization, antibody positive rates for type Ⅰ and Ⅲ poliovirus were 100%, except 98.61% (71) for type Ⅰ poliovirus in 2014. The neutralizing antibody titer of type Ⅰ and Ⅲ poliovirus was higher in 2016 and 2018 than that in 2012 and 2014 ( P<0.001). The average titer of tOPV were (6.05±0.15) and (6.16±0.12) lgCCID 50 per dose in 2012 and 2014. The average titer of bOPV were (6.88±0.21) and (6.26±0.14) lgCCID 50 per 100 μl in 2016 and 2018 ( P<0.001). Conclusion:Before and after the adjustment of polio vaccine immunization strategy in Beijing, the basic immunization success rate of the IPV-bOPV sequential immunization schedule was good as well as full tOPV schedule. The level of polio antibody produced by the IPV-bOPV sequential immunization schedule was higher. After adjustment, bOPV titer in 2016 was significantly higher than those before adjustment, while bOPV titer decreased significantly in 2018.
